Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia

​ Conditions: Breast Cancer

Interventions: Drug: Ribociclib; Drug: Letrozole; Drug: Anastrozole

Sponsors: Novartis Pharmaceuticals

Not yet recruiting Conditions: Breast Cancer
Interventions: Drug: Ribociclib; Drug: Letrozole; Drug: Anastrozole
Sponsors: Novartis Pharmaceuticals
Not yet recruiting